{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IPI-145+%28duvelisib%29",
    "query": {
      "intervention": "IPI-145 (duvelisib)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 42,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IPI-145+%28duvelisib%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T21:03:38.305Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07001384",
      "title": "A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Lymphoma Kinase",
        "Anaplastic Large Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Duvelisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-08-08",
      "completion_date": "2031-08-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07001384"
    },
    {
      "nct_id": "NCT05010005",
      "title": "A Study of Ruxolitinib and Duvelisib in People With Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T-cell Lymphomas",
        "NK-Cell Lymphomas",
        "T-cell Prolymphocytic Leukemia",
        "T-cell Large Granular Lymphocyte Leukemia"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Duvelisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2021-08-12",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 9,
      "location_summary": "Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05010005"
    },
    {
      "nct_id": "NCT02049515",
      "title": "A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "IPI-145",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SecuraBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2013-12",
      "completion_date": "2020-06-12",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • Denver, Colorado • Fort Myers, Florida + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02049515"
    },
    {
      "nct_id": "NCT03372057",
      "title": "A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Duvelisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SecuraBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2018-02-22",
      "completion_date": "2023-12-22",
      "has_results": true,
      "last_update_posted_date": "2025-03-07",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 19,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03372057"
    },
    {
      "nct_id": "NCT02783625",
      "title": "Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Relapsed/Refractory T-cell Lymphomas"
      ],
      "interventions": [
        {
          "name": "Romidepsin",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "duvelisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2016-05-23",
      "completion_date": "2026-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 11,
      "location_summary": "Stanford, California • Boston, Massachusetts • St Louis, Missouri + 7 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02783625"
    },
    {
      "nct_id": "NCT05057247",
      "title": "Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "Recurrent Squamous Cell Carcinoma of the Head and Neck",
        "Metastatic Head and Neck Cancer",
        "Advanced Head and Neck Cancer",
        "Advanced Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Duvelisib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartik Sehgal, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-10-14",
      "completion_date": "2024-06-13",
      "has_results": true,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05057247"
    },
    {
      "nct_id": "NCT01882803",
      "title": "A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Indolent Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Duvelisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SecuraBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2013-06-17",
      "completion_date": "2020-11-18",
      "has_results": true,
      "last_update_posted_date": "2023-09-07",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Whittier, California • Denver, Colorado + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01882803"
    },
    {
      "nct_id": "NCT01947777",
      "title": "Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "IPI-145",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SecuraBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-10",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01947777"
    },
    {
      "nct_id": "NCT02307461",
      "title": "Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "IPI-145 (duvelisib)",
          "type": "DRUG"
        },
        {
          "name": "IPI-145",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SecuraBio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 103,
      "start_date": "2014-11",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307461"
    },
    {
      "nct_id": "NCT05065866",
      "title": "Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Myeloma",
        "Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "BMS-986345",
          "type": "DRUG"
        },
        {
          "name": "Duvelisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2021-11-18",
      "completion_date": "2024-04-24",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-09-29T21:03:38.305Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05065866"
    }
  ]
}